Patient leaflet - Refixia 1000 IU powder and solvent for solution for injection
What Refixia® is and what it is used for
What Refixia® is
Refixia® contains the active substance nonacog beta pegol. It is a long-acting version of factor
IX. Factor IX is a protein
naturally found in the blood that helps to stop bleeding.
What Refixia® is used for
Refixia® is used to treat and prevent bleeding in all groups of patients with haemophilia B (inborn factor
IX deficiency).
In patients with haemophilia B, factor
IX is missing or does not
work properly. Refixia® replaces this faulty or missing factor
IX and
helps blood to form clots at the site of bleeding.
2.
What you need to know before you use
Refixia®
Do not use Refixia®
•
if you are allergic to the active substance or any of the other
ingredients of this medicine (listed in section 6).
•
if you are allergic to hamster proteins.
If you are not sure if either of the above applies to you, talk to your doctor before using this medicine.
Warnings and precautions
Traceability
It is important to keep a record of the batch number of your Refixia. So, every time you get a new package of Refixia, note down the date and the batch number (which is on the packaging after Lot) and keep this information in a safe place.
Allergic reactions and development of inhibitors
There is a rare risk that you may experience a sudden and severe allergic reaction (e.g. anaphylactic reaction) to Refixia®. Stop the injection and contact your doctor or an emergency unit immedi-ately if you have signs of an allergic reaction such as rash, hives, weals, itching of large areas of skin, redness and/or swelling of lips, tongue, face or hands, difficulty in swallowing or breathing, shortness of breath, wheezing, tightness of the chest, pale and cold skin, fast heartbeat, and/or dizziness.
Your doctor may need to treat you promptly for these reactions. Your doctor may also carry out a blood test to check if you have developed factor
IX inhibitors (neutralising antibodies) against
your medicine, as inhibitors may develop together with allergic reactions. If you have such inhibitors, you may have a higher risk of sudden and severe allergic reactions (e.g. anaphylactic reaction) during future treatment with factor
IX.
Because of the risk of allergic reactions with factor
IX, your initial
treatment with Refixia® should be given in a medical clinic or in the presence of health care professionals where proper medical care for allergic reactions can be provided if needed.
Talk to your doctor immediately if your bleeding does not stop as expected or if you have to significantly increase the amount of Refixia® you need to stop a bleed. Your doctor will do a blood test to check if you have developed inhibitors (neutralising antibodies) against Refixia®. The risk for developing inhibitors is highest in people who have not been treated with factor
IX medicines
before, typically small children.
Blood clots
Tell your doctor, if any of the following apply to you as there is an increased risk of blood clots during treatment with Refixia®:
•
you have recently had surgery
•
you suffer from other serious illness e.g. liver disease, heart
disease, or cancer
•
you have risk factors for heart disease e.g high blood pressure,
obesity, or smoking.
Kidney disorder (nephrotic syndrome)
There is a rare risk of developing a specific kidney disorder called “nephrotic syndrome” following high doses of factor
IX in haemo
-philia B patients with factor
IX inhibitors and a history of allergic
reactions.
Catheter-related problems
If you have a central venous access device (CVAD), you may develop infections or blood clots at the site of the catheter.
Other medicines and Refixia®
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using Refixia®.
Driving and using machines
Refixia® has no influence on the ability to drive and use machines.
Refixia® contains sodium
This medicine contains less than 1
mmol sodium (23 mg) per vial,
that is to say essentially “sodium-free”. In case of treatment with multiple vials, the total sodium content should be taken into consideration.
3.
How to use Refixia®
Treatment with Refixia® will be started by a doctor who is experi-enced in the care of patients with haemophilia B. Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure about how to use Refixia®.
Your doctor will calculate the right dose for you. The dose will depend on your weight and what the medicine is being used for.
Prevention of bleeding
The usual dose of Refixia® is 40
international units (IU) per kg of body weight. This is given as one injection every week. Your doctor may choose another dose or change how often the injections should be given, based on your need.
Treatment of bleeding
The usual dose of Refixia® is 40
international units (IU) per kg of body weight. Depending on the location and the severity of bleed-ing you may need a higher dose (80
IU per kg) or extra injections.
Discuss with your doctor the dose and number of injections you need.
Use in children and adolescents
Refixia® can be used in children and adolescents of all ages. The dose in children and adolescents is also calculated according to body weight and is the same dose as for adults.
How Refixia® is given
Refixia® is available as powder and solvent that is made up into a solution (reconstitution) and given as an injection into a vein. See “Instructions on how to use Refixia®” for more information.
If you use more Refixia® than you should
If you use more Refixia® than you should, contact your doctor.
If you have to significantly increase the amount of Refixia® you need to stop a bleed, talk to your doctor immediately. For further information, see section 2 “Allergic reactions and development of inhibitors”.
If you forget to use Refixia®
If you forget a dose, inject the missed dose as soon as you remember. Do not inject a double dose to make up for a forgotten dose. If you are in doubt contact your doctor.
If you stop using Refixia®
If you stop using Refixia® you may no longer be protected against bleeding or a current bleed may not stop. Do not stop using Refixia® without talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor.
4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Allergic reactions are possible with this medicine.
If sudden and severe allergic reactions (e.g. anaphylactic reactions) occur, the injection must be stopped immediately. You must contact your doctor or an emergency unit immediately if you have early signs of a severe allergic reaction (anaphylactic reaction) such as:
•
difficulty in swallowing or breathing
•
shortness of breath or wheezing
•
chest tightness
•
redness and/or swelling of the lips, tongue, face or hands
•
rash, hives, weals or itching
•
pale and cold skin, fast heartbeat, and/or dizziness (low blood pressure).
For children not previously treated with factor IX medicines, inhibitors (see section 2) may form commonly (up to 1 in 10 patients). If this happens, the medicine may stop working properly and your child may experience persistent bleeding. If this happens, you should contact your doctor immediately.
The following side effects have been observed with Refixia®:
Common side effects (may affect up to 1 in 10 people)
•
allergic reactions (hypersensitivity). This may become severe and could be life-threatening (anaphylactic reactions)
•
itching (pruritus)
•
skin reactions at the site of injection
•
feeling sick (nausea)
•
feeling very tired.
•
rash
•
Children not previously treated with factor IX medicines:
neutralising antibodies (inhibitors), anaphylactic reactions.
Uncommon side effects (may affect up to 1 in 100 people)
•
heart palpitations
•
hot flush.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
5.
How to store Refixia®
Keep this medicine out of the sight and reach of children.
Do not use Refixia® after the expiry date which is stated after “EXP” on the carton and on the vial and the pre-filled syringe labels. The expiry date refers to the last day of that month.
Store in a refrigerator (2 °C – 8 °C). Do not freeze. Keep the vial in the outer carton in order to protect from light.
Refixia® may be taken out of the refrigerator for a maximum per-iod of 1 year and stored at room temperature (up to 30 °C). Please record on the carton the date Refixia® is removed from the refrigerator and placed at room temperature. This new expiry date should never exceed the one initially mentioned on the outer car-ton. If the medicine has not been used before the new expiry date, it should be disposed of. After storage at room temperature the medicine must not be put back in the refrigerator.
Use the injection immediately after making up the solution (reconstitution). If it cannot be used immediately, use within 24
hours if stored in a refrigerator at 2 °C – 8 °C or within 4 hours if stored out of the refrigerator at a maximum temperature of 30 °C
The powder in the vial appears as a white to off-white powder. Do not use the powder if the colour has changed.
The reconstituted solution will be clear and colourless to slightly yellow. Do not use the reconstituted solution if you notice any particles or discolouration.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
Contents of the pack and other
information
What Refixia® contains
•
The active substance is nonacog beta pegol (pegylated human coagulation factor
IX (rDNA)). Each vial of Refixia® contains nominally 500
IU, 1000 IU, 2000 IU or 3000 IU nonacog beta pegol corresponding to approximately 125
IU/ml, 250 IU/ml,
500 IU/ml or 750 IU/ml respectively after reconstitution with histidine solvent.
•
The other ingredients in the powder are sodium chloride, histidine, sucrose, polysorbate 80, mannitol, sodium hydroxide and hydrochloric acid. See section 2 “Refixia contains sodium”.
•
The ingredients in the sterilised solvent are histidine, water for injections, sodium hydroxide and hydrochloric acid.
What Refixia® looks like and contents of the pack
•
Refixia® is provided as a powder and solvent for solution for injection (500 IU, 1000 IU, 2000 IU or 3000 IU powder in a vial and 4 ml solvent in a pre-filled syringe, a plunger rod with a vial adapter - pack size of 1). Not all strengths may be marketed.
•
The powder is white to off-white and the solvent is clear and colourless.
Marketing Authorisation Holder and Manufacturer
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd, Denmark
This leaflet was last revised in 11/2025
Regulatory Operations
Insert: 2010-470x462-011
LIFT - Current 1
1 language N9-GP Refixia
Patient, prof
Package leaflet: Information for the user
Refixia®
500
IU powder and solvent for solution for injection
1000
IU powder and solvent for solution for injection
2000
IU powder and solvent for solution for injection
3000 IU powder and solvent for solution for injection
nonacog beta pegol
8-9059-01-001-7
Refixia® is a trademark owned by Novo Nordisk Health Care AG, Switzerland.
© 2023
Novo Nordisk A/S
VV-LAB-137061 2.0
.
Overview
Vial with Refixia® powder
Plastic cap
Rubber stopper
(under plastic cap)
Vial adapter
Protective cap
Spike
(under protective paper)
Protective
paper
Pre-filled syringe with solvent
Syringe cap
Syringe tip
(under syringe cap)
Plunger
Instructions on how to use Refixia®
Read these instructions carefully before using Refixia®.
Refixia® is supplied as a powder. Before injection a solution must be made up (reconstituted) with the solvent supplied in the syringe. The solvent is a histidine solution. The reconstituted solution must be injected into a vein (intravenous (IV) injection). The equipment in this package is designed to reconstitute and inject Refixia®.
You will also need an infusion set (tubing and butterfly needle), sterile alcohol swabs, gauze pads and plasters. These items are not included in the Refixia® package.
Do not use the equipment without proper training from your doctor or nurse.
Always wash your hands and ensure that the area around you is clean.
When you prepare and inject medicine directly into the veins, it is important to use a clean and germ-free (aseptic) technique. Incorrect technique can introduce germs that can infect the blood.
Do not open the equipment until you are ready to use it.
Do not use the equipment if it has been dropped, or if it is damaged. Use a new package instead.
Do not use the equipment if it has expired. Use a new package instead. The expiry date is printed on the outer carton, on the vial, on the vial adapter, and on the pre-filled syringe.
Do not use the equipment if you suspect it is contaminated. Use a new package instead.
Do not dispose of any of the items until after you have injected the reconstituted solution.
The equipment is for single use only.
1.
Prepare the vial and the
syringe
•
Take out the number of
Refixia® packages you need.
•
Check the expiry date.
•
Check the name, strength and colour of the package, to make sure it contains the correct product.
•
Wash your hands and dry them properly using a clean towel or air dry.
•
Take the vial, the vial adapter
and the pre-filled syringe out of the carton. Leave the plunger rod untouched in the carton.
•
Bring the vial and the
pre-filled syringe to room temperature. You can do this by holding them in your hands until they feel as warm as your hands.
•
Do not use any other way to warm the vial and pre-filled syringe.
A
•
Remove the plastic cap from the vial. If the plastic cap is loose or missing, do not use the vial.
•
Wipe the rubber stopper
with a sterile alcohol swab and allow it to air dry for a few seconds before use to ensure that it is as germ free as possible.
•
Do not touch the rubber
stopper with your fingers as this can transfer germs.
B
•
Remove the protective
paper from the vial adapter.
If the protective paper is
not fully sealed or if it is broken, do not use the vial adapter.
Do not take the vial
adapter out of the protective cap with your fingers. If you touch the spike on the vial adapter, germs from your fingers can be transferred.
C
4.
Reconstitute the powder with
the solvent
•
Place the vial on a flat and
solid surface.
•
Turn over the protective cap, and snap the vial adapter onto the vial.
Once attached, do not
remove the vial adapter from the vial.
D
•
Lightly
squeeze the protective cap with your thumb and index finger as shown.
Remove the protective cap
from the vial adapter.
Do not lift the vial adapter
from the vial when removing the protective cap.
E
•
Grasp the plunger rod by the
wide top end and take it out of the carton. Do not touch the sides or the thread of the plunger rod. If you touch the sides or the thread, germs from your fingers can be transferred.
•
Immediately connect the plunger rod to the syringe by turning it clockwise into the plunger inside the pre-filled syringe until resistance is felt.
•
Hold the pre-filled syringe slightly tilted with the vial pointing downwards.
•
Push the plunger rod to inject all the solvent into the vial.
I
•
Keep the plunger rod pressed down and swirl the vial gently until all the powder is dissolved.
Do not shake the vial as
this will cause foaming.
•
Check the reconstituted solution. It must be clear and colourless to slightly yellow and no particles should be visible. If you notice particles or discolouration, do not use it. Use a new package instead.
J
•
Keep the plunger rod
pushed completely in.
•
Turn the syringe
with the vial upside down.
•
Stop pushing the plunger
rod and let it move back on its own while the reconstituted solution fills the syringe.
•
Pull the plunger rod
slightly downwards to draw the reconstituted solution into the syringe.
•
In case you only need part
of the entire vial, use the scale on the syringe to see how much reconstituted solution you withdraw, as instructed by your doctor or nurse.
If, at any point, there is air in
the syringe, inject the air back into the vial.
•
While holding the vial upside
down, tap the syringe gently to let any air bubbles rise to the top.
•
Push the plunger rod slowly until all air bubbles are gone.
K
L
Disposal
•
After injection, safely dispose of all unused Refixia® solution, the syringe with the infusion set, the vial with the vial adapter and other waste materials as instructed by your pharmacist.
Do not throw it out with the ordinary household waste.
M
Do not disassemble the equipment before disposal.
Do not reuse the equipment.
2.
Attach the vial adapter
3.
Attach the plunger rod and
the syringe
•
Remove the syringe cap from the pre-filled syringe by bending it down until the perforation breaks.
•
Do not touch the syringe tip under the syringe cap. If you touch the syringe tip, germs from your fingers can be transferred.
If the syringe cap is loose
or missing, do not use the pre-filled syringe.
G
•
Screw the pre-filled syringe securely onto the vial adapter until resistance is felt.
H
Plunger rod
Contents
The package contains:
•
1 vial with Refixia® powder
•
1 vial adapter
•
1 pre-filled syringe with
solvent
•
1 plunger rod (placed
under the syringe)
If your dose requires more than one vial, repeat steps A to J with additional vials, vial adapters and pre-filled syringes until you have reached your required dose.
5.
Inject the reconstituted solution
Refixia® is now ready to inject into your vein.
•
Inject the reconstituted solution as instructed by your doctor or nurse.
•
Inject slowly over 1 to 3 minutes.
•
Do not mix Refixia® with any other intravenous infusions or medicines.
Injecting Refixia® via needleless connectors for intravenous (IV) catheters
Caution: The pre-filled syringe is made of glass and is designed to be compatible with standard luer-lock connections. Some needleless connectors with an internal spike are incompatible with the pre-filled syringe. This incompatibility may prevent administration of the medicine and/or result in damage to the needleless connector.
Injecting the solution via a central venous access device (CVAD) such as a central venous catheter or a subcutaneous port:
•
Use a clean and germ-free (aseptic) technique. Follow the instructions for proper use for your connector and CVAD in consultation with your doctor or nurse.
•
Injecting into a CVAD may require using a sterile 10 ml plastic syringe for withdrawal of the reconstituted solution. This should be done right after step J.
•
If the CVAD line needs to be flushed before or after Refixia® injection, use sodium chloride 9
mg/ml solution for injection.
Refixia® is recommended to be used immediately after it has been reconstituted. This is because if left, the medicine may no longer be sterile and could cause infections.
If you cannot use the reconstituted Refixia® solution immediately, it should be used within 4
hours when stored at
room temperature (up to 30 °C) and within 24
hours when
stored in a refrigerator (2 °C – 8 °C). Store the reconstituted product in the vial.
Do not freeze reconstituted Refixia® solution or store it in syringes.
Keep reconstituted Refixia® solution out of direct light.
Scale
•
Unscrew the vial adapter with the vial.
•
Do not touch the syringe
tip. If you touch the syringe tip, germs from your fingers can be transferred.
Thread
Wide top end
F
VV-LAB-137061 2.0 .